Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Judith Smith, PharmD, BCOP, CPHQ, FCCP,…
Browsing: General
Fermin Sanchez-Guijo, MD, PhD, of Hospital ClÃnico Universitario de Salamanca, Salmanca, Spain, speaks to us about the role of mesenchymal…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Ernst Holler, MD,…
Anti-thymocyte globulin (ATG) is immunosuppressive antibody that has been around for >30 years, which is used to prevent graft-versus-host disease…
Speaking from the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Genovefa Papanicolaou,…
In this video, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal,…
Denis Claude Roy, MD, FRCP, of the University of Montreal, Montreal, Canada, is involved in developing a technique for eradicating…
In recent years, there has been a massive increase in the number of different immunotherapeutic agents that can be used…
Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa…
Edward L. Nelson, MD, UC Irvine Health talks about hoe RET Inhibitors May Be Approved this Year | Systems-Based Approach…
Edward L. Nelson, MD, UC Irvine Health talk about PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel Wolff, MD,…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, held in Denver, CO, Jill Kolesar, PharmD, MS, BCPS, FCCP,…
Edward L. Nelson, MD, UC Irvine Health says to Enroll Patients in Umbrella or Basket Trials | PI3-kinase Did Not…
In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic…
With the increased use of next-generation sequencing (NGS) to identify mutations in patient’s own cancer cells, the off-label usage of…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ginah Nightingale, PharmD, BCOP, of Thomas…
Ginah Nightingale, PharmD, BCOP, of Thomas Jefferson University, Philadelphia, PA, discusses why cognitive impairment as a result of chemotherapy is…
There is increasing evidence to suggest that chemotherapy contributes to changes in cognition. In this interview, Ginah Nightingale, PharmD, BCOP,…
Joseph Bubalo, PharmD, BCOP, BCPS, of Oregon Health and Science University Hospital, Portland, OR, speaking from the 2018 Hematology/Oncology Pharmacy…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Jeanne McCarthy-Kaiser, PharmD, BCOP, of the…
Edward L. Nelson, MD, UC Irvine Health explains Number of Molecular Targets Are Overwhelming Practitioners | Practitioners Must Know What…
Edward L. Nelson, MD, UC Irvine Health explains Whether to ReBiopsy a Tumor | Give Practitioners Understanding of Modalities at…
Edward L. Nelson, MD, UC Irvine Health explains Topics Covered in ASCO 2018 | Precision Medicine, Next-Gen Sequencing, Tumor Cells,…
John Gribben, of Barts Cancer Institute, London, UK, discusses making CAR T-cells happen in Europe. This video was recorded at…
HARMONY is Europe’s largest public-private partnership for big data in hematology. Here, Jesús MarÃa Hernández Rivas, HARMONY Alliance Project Coordinator,…
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients…
Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in…
Precision, or personalized, medicine has often been regarded as the future of cancer treatment. In this interview, Howard Burris, MD,…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.
CAR T-cells represent an important step forward in the treatment of a variety of hematological malignancies. At the American Society…
Howard A. “Skip” Burris III, MD, FACP, FASCO, explains some of the new and exciting concepts in clinical trial design
Eunice Wang, MD, talks about The most exciting data coming out of the 2018 Annual Meeting
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how Watson is…
Howard A. “Skip” Burris III, MD, FACP, FASCO, talks about his goals for the 2019 Annual Meeting.
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how data from…
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, talks about how augmented…
The British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, had a record number of clinical experts in…
Could patients who remain MRD negative long-term whilst on maintenance treatment cease treatment? Here, Ola Landgren, MD, PhD, from Memorial…
Very soon, minimal residual disease (MRD) testing will become a routine part of clinical practice. Therefore, it is important that…
Newer treatments for hematological malignancies, including immunotherapies and cellular therapies, are more targeted than historical chemotherapies. This means that the…
The measurement and use of minimal residual disease (MRD) is an exciting development in the world of hematological oncology. So,…
Randall A. Oyer, MD, Dr. Oyer explains how ACCC is contributing to the work being done to address disparities in…
Mark Levis, MD, PhD, shares his thoughts on the most exciting clinical trial data coming out of the 2018 Annual…
Noa Biran, MD, shares her opinion on the most exciting clinical data presented at the 2018 Annual Meeting Annual Meeting.
Gareth Morgan, MD, PhD, FRCP, FRCPath, from the University of Arkansas for Medical Sciences, Little Rock, AR, gives a brief…
Allogenic stem cell transplants are the only curative therapy available for several hematological diseases; however, graft-versus-host disease (GvHD) is a…
Randall A. Oyer, MD, explains the immunotherapy data coming out of the Annual Meeting 2018 and the purpose of the…
Ivo Abraham, PhD, RN, shares his thoughts on demonstrating the value of cancer care in today’s oncology landscape at Annual…
Ivo Abraham, PhD, RN, shares his perspective on biosimilar pricing and reimbursement at Annual Meeting 2018.